CN107941722A - Blood sample analysis tests system - Google Patents
Blood sample analysis tests system Download PDFInfo
- Publication number
- CN107941722A CN107941722A CN201711356235.4A CN201711356235A CN107941722A CN 107941722 A CN107941722 A CN 107941722A CN 201711356235 A CN201711356235 A CN 201711356235A CN 107941722 A CN107941722 A CN 107941722A
- Authority
- CN
- China
- Prior art keywords
- sample
- blood
- plasma
- glucose
- concentration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000004369 blood Anatomy 0.000 title claims abstract description 106
- 239000008280 blood Substances 0.000 title claims abstract description 106
- 238000012360 testing method Methods 0.000 title claims abstract description 34
- 238000004458 analytical method Methods 0.000 title claims abstract description 16
- 210000002381 plasma Anatomy 0.000 claims abstract description 92
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims abstract description 60
- 239000008103 glucose Substances 0.000 claims abstract description 60
- 102000001554 Hemoglobins Human genes 0.000 claims abstract description 52
- 108010054147 Hemoglobins Proteins 0.000 claims abstract description 52
- 206010018910 Haemolysis Diseases 0.000 claims abstract description 39
- 230000008588 hemolysis Effects 0.000 claims abstract description 39
- 239000007788 liquid Substances 0.000 claims abstract description 35
- 150000002632 lipids Chemical class 0.000 claims abstract description 24
- 238000001514 detection method Methods 0.000 claims abstract description 21
- 238000012545 processing Methods 0.000 claims abstract description 10
- 239000002002 slurry Substances 0.000 claims description 10
- 238000010521 absorption reaction Methods 0.000 claims description 4
- 102000004190 Enzymes Human genes 0.000 claims description 3
- 108090000790 Enzymes Proteins 0.000 claims description 3
- 238000005259 measurement Methods 0.000 claims description 3
- 238000005375 photometry Methods 0.000 claims description 3
- 235000009754 Vitis X bourquina Nutrition 0.000 claims description 2
- 235000012333 Vitis X labruscana Nutrition 0.000 claims description 2
- 240000006365 Vitis vinifera Species 0.000 claims description 2
- 235000014787 Vitis vinifera Nutrition 0.000 claims description 2
- 238000004364 calculation method Methods 0.000 claims description 2
- 238000007689 inspection Methods 0.000 claims 1
- 239000000306 component Substances 0.000 description 42
- 238000000034 method Methods 0.000 description 6
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- 238000003556 assay Methods 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 206010020850 Hyperthyroidism Diseases 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 206010054805 Macroangiopathy Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 208000010513 Stupor Diseases 0.000 description 1
- 208000009443 Vascular Malformations Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000001412 amines Chemical group 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 238000004159 blood analysis Methods 0.000 description 1
- 239000012503 blood component Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 239000003093 cationic surfactant Chemical group 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 102000018146 globin Human genes 0.000 description 1
- 108060003196 globin Proteins 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 239000003219 hemolytic agent Substances 0.000 description 1
- 208000007475 hemolytic anemia Diseases 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- NNFCIKHAZHQZJG-UHFFFAOYSA-N potassium cyanide Chemical group [K+].N#[C-] NNFCIKHAZHQZJG-UHFFFAOYSA-N 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000009711 regulatory function Effects 0.000 description 1
- 208000026775 severe diarrhea Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/17—Systems in which incident light is modified in accordance with the properties of the material investigated
- G01N21/25—Colour; Spectral properties, i.e. comparison of effect of material on the light at two or more different wavelengths or wavelength bands
- G01N21/31—Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/75—Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated
- G01N21/77—Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated by observing the effect on a chemical indicator
- G01N21/78—Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated by observing the effect on a chemical indicator producing a change of colour
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N27/00—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means
- G01N27/26—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating electrochemical variables; by using electrolysis or electrophoresis
Landscapes
- Physics & Mathematics (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Electrochemistry (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Plasma & Fusion (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
A kind of blood sample analysis tests system, including：Sample division, the first sample and the second sample are divided into by the blood sample of input test system；Haemolysis processing unit, for carrying out haemolysis to receiving sample；Glucose detection portion, the concentration of glucose of sample is received for detecting；Hemoglobin test section, the hemoglobin concentration of sample is received for detecting；Haemocyte/blood plasma is than calculating part, for calculating haemocyte in blood sample/blood plasma ratio；Whole blood liquid component is than operational part, the liquid component ratio of the whole blood for calculating blood sample；Plasma lipid component is than operational part, for determining plasma lipid component ratio；Plasma glucose calculating part, it is used to calculate plasma glucose concentration.
Description
Technical field
The present invention relates to a kind of automatic analysis system, and test system is automatically analyzed more particularly, to a kind of blood sample.
Background technology
Blood is important component in human body, at least contains 4000 kinds of heterogeneities in blood of human body, flows through in human body
Each organ, tissue, participate in metabolism, regulatory function and the internal and external environment balance for maintaining human body of human body.Human body is any
Specific biomarker can be all produced during position generation pathologic change to be discharged into blood, reflection detected person is in a timing
Physical condition in phase.Medical worker by the change of blood constituent content can measured without any obvious diseased sign or
Only slight impression is not in due course, finds that some hide disease in advance.Therefore in Accurate Determining blood of human body various composition content, one
It has been condition-inference and the essential link of routine physical examination since straight, is that clinician clarifies a diagnosis, understands conditions of patients
Development, assesses the main means of therapeutic effect.
Every kind of blood constituent has its specific physiological significance and clinical meaning.Hemoglobin（Hemoglobin, Hb）It is
The spherical macromolecular compound being made of ferroheme and globin, its main Physiological Function are to transport oxygen and carbon dioxide, it
Oxygen can be carried from lung and tissue is shipped for by arterial blood, and can carry carbon dioxide caused by tissue metabolism via vein
Blood is sent to lung and then excretes；It can also play cushioning effect to acidic materials, participate in internal acid-base balance and adjust.When its disease
When rationality is relatively low often caused by hematopoiesis function exhaustion, borne materials lack and lose blood, when hemoglobin pathologic is higher,
It is common in the diseases such as large-area burns, severe diarrhea, hyperthyroidism, vascular malformation and heart and lung diseases.
Blood glucose（Glucose, Glu）Refer to the glucose in blood, be the main energy sources of internal cellular activity.Blood
The content of middle blood glucose, which needs to be maintained at a certain range, could maintain the normal work of in-vivo tissue and organ.Long-term hypoglycemia meeting
Cause human body failure of memory, slow in reacting, dull-witted, stupor, or even trigger cerebrovas-cularaccident and miocardial infarction；Work as blood-sugar content
When being higher than normal value for a long time, microvascular and macroangiopathy can be caused, patient's eye, heart, kidney, blood vessel, nerve etc. can be made
Chronic lesion and dysfunction occur for tissue.
Therefore, level that is regular or detecting the index such as hemoglobin, blood glucose in blood sample regularly is most effective
Prevention and treatment these diseases method, for judging disease in time, instruct diagnose and treat that there is important clinic
Meaning.
In current blood component analyzing, usually draw blood to the artery or finger tip of human body, obtain isolated blood sample
This, analyzes using to the whole blood sample after blood sample haemolysis, therefore the testing result obtained is the Portugal in whole blood sample
Grape sugared content, it is different from the glucose content in the blood plasma for needing to obtain in clinical analysis.To solve the above-mentioned problems,
201110166156.3 patent of invention discloses a kind of while detects hemoglobin and the blood of blood sugar concentration in blood sample sample
Liquid detecting system, wherein by using the haemocyte in blood and the ratio of blood plasma and haemocyte liquid component ratio and
The liquid component ratio of blood plasma, so as to obtain extremely close to the value of actual plasma glucose concentration.By blood plasma in the invention
Liquid component ratio and the liquid component ratio of haemocyte be preset as fixed value, the blood plasma moisture accounting normally recognized is usually
Fixed value, but for hemolytic anemia patient due to its hematoclasis, component is mixed into blood plasma in red blood cell, its blood plasma
Component differs larger with normal value, and there are large error for the plasma glucose concentration determined by this method；Need to increase specific
Water content detecting instrument device measurement blood plasma moisture ratio, can ensure the accuracy of measurement result.
The content of the invention
A kind of improvement of the present invention as 201110166156.3 patents of invention, it is proposed that blood sample analysis test system
System, it can also be obtained and accurately survey for blood plasma moisture than abnormal blood analysis on the basis of instrument is not increased
Measure result.
As one aspect of the present invention, there is provided a kind of blood sample analysis tests system, including：Haemolysis processing unit, is used
In to receiving sample progress haemolysis；Glucose detection portion, the concentration of glucose of sample is received for detecting；Hemoglobin detects
Portion, the hemoglobin concentration of sample is received for detecting；Haemocyte/blood plasma is thin for calculating blood in blood sample than calculating part
Born of the same parents/blood plasma ratio；Whole blood liquid component is than operational part, the liquid component ratio of the whole blood for calculating blood sample；Plasma glucose
Sugared calculating part, it is used to calculate plasma glucose concentration；Sample division is further included, plasma lipid component is than operational part and control
Portion processed；The blood sample of input test system is divided into the first sample and the second sample by the sample division；Control unit
The hemoglobin test section is controlled to determine the hemoglobin concentration of first sample；The plasma lipid component compares operational part
Based on the hemoglobin concentration of first sample, plasma lipid component ratio is determined；Control unit control second examination
After sample carries out haemolysis processing by haemolysis processing unit, the glucose detection portion and hemoglobin test section is controlled to detect haemolysis
The concentration of glucose and hemoglobin concentration of the second sample afterwards；Haemocyte/the blood plasma is than calculating part, based on described first
The hemoglobin concentration of sample, the hemoglobin concentration of the second sample after haemolysis, calculates haemocyte/blood plasma ratio in blood sample；
The whole blood liquid component is than operational part, haemocyte/blood plasma in the blood sample calculated based on haemocyte/blood plasma than calculating part
Than determining the liquid component ratio of the whole blood of blood sample；Plasma glucose calculating part, compares operational part based on whole blood liquid component
The liquid component ratio of definite whole blood, plasma lipid component are than plasma lipid component ratio and glucose that operational part determines
The concentration of glucose of the second sample after the haemolysis of test section detection, determines concentration of glucose in blood plasma.
Preferably, the plasma lipid component is based on following formula than operational part and calculates plasma lipid component ratio b1=(bSlurry+
V1×bBorn of the same parents)/(1+ V1), wherein bSlurryFor plasma lipid component ratio constant, bBorn of the same parentsFor haemocyte liquid component rate constant, V1For root
The broken haemocyte determined according to the hemoglobin concentration of the first sample/blood plasma ratio.
Preferably, the haemocyte/blood plasma is than calculating part, based on the hemoglobin concentration of first sample, after haemolysis
The hemoglobin concentration of second sample, calculates haemocyte/blood plasma in blood sample and compares Vb=V2- V1, wherein V2For according to haemolysis
The haemocyte that the hemoglobin concentration of the second sample determines afterwards/blood plasma ratio, V1It is true for the hemoglobin concentration according to the first sample
Fixed broken haemocyte/blood plasma ratio.
Preferably, the whole blood liquid component is based on following formula than operational part and calculates whole blood liquid component ratio b2=a1×bSlurry
+ a2×bBorn of the same parents；Wherein a2For haemocyte/whole blood ratio of the second sample after haemolysis, a2=Vb/(Vb+ 1), a1For the second examination after haemolysis
The blood plasma of sample/whole blood ratio, a1=1-a2。
Preferably, the plasma glucose calculating part is based on following formula and calculates concentration of glucose 1 × b1/b2 of ρ=ρ in blood plasma,
The concentration of glucose of the second sample after the haemolysis that wherein ρ 1 detects for glucose detection portion.
Preferably, the hemoglobin test section measures the hemoglobin concentration for receiving sample based on absorption photometry.
Preferably, the glucose detection portion measures the concentration of glucose for receiving sample based on Enzyme Electrode.
Preferably, the glucose detection portion determines to receive the concentration of glucose of sample based on enzymic colorimetric.
Preferably, the haemocyte liquid component rate constant bBorn of the same parentsFor 65%.
Preferably, the plasma lipid component ratio constant bSlurryFor 90%.
Brief description of the drawings
Fig. 1 is the structure diagram of the blood sample analysis test system of the embodiment of the present invention.
Embodiment
The embodiment of the present invention is described below in detail, the example of the embodiment is shown in the drawings, wherein from beginning to end
Same or similar label represents same or similar element or has the function of same or like element.Below with reference to attached
The embodiment of figure description is exemplary, and is only used for explaining the present invention, and is not considered as limiting the invention.Moreover, should
Work as understanding, the feature not mutual exclusion of various embodiments described here, and can be combined and transformation mistake various
Exist in journey.
Blood sample analysis test system in the embodiment of the present invention, referring to Fig. 1, including sample division 10, at haemolysis
Reason portion 20, glucose detection portion 30, hemoglobin test section 40, plasma lipid component is than operational part 50, and haemocyte/blood plasma is than meter
Calculation portion 60, whole blood liquid component is than operational part 70, plasma glucose calculating part 80 and control unit 90.
Sample division 10 is used to need the sample detected, and the blood sample of input test system is divided into the first examination by it
Sample and the second sample；The volume ratio of first sample and the second sample can be 50：50, can also 40：60 or 30：70.It is excellent
Choosing, the volume ratio of the first sample and the second sample is 30：70.
Haemolysis processing unit 20, for carrying out haemolysis for receiving sample, can use hemolytic agent of the prior art for example
Organic quaternary amine, potassium cyanide, cationic surfactant etc. are used as hemolyzing reagent.After haemolysis, the hemocytolysis of sample is received,
Form whole blood sample.
Glucose detection portion 30, the concentration of glucose of sample is received for detecting.Glucose detection portion 30 can use enzyme
Electrode method or enzymic colorimetric determine that it receives the concentration of glucose of sample.The of 90 Control Assay division 10 of control unit division
Two samples, by a part of input glucose test section 30 of obtained whole blood sample, determine whole blood by haemolysis processing unit 20
This concentration of glucose ρ 1.
Hemoglobin test section 40, the hemoglobin concentration of sample is received for detecting.Hemoglobin test section 40 can be with
Including absorption spectrometer, the hemoglobin concentration for receiving sample is measured by absorption photometry.90 Control Assay of control unit divides
The first sample that portion 10 divides is by hemoglobin test section 40, for measuring the hemoglobin concentration of the first sample；Control unit
90 go back Control Assay division 10 division the second sample by haemolysis processing unit 20 after, the remainder of obtained whole blood sample
Hemoglobin test section is inputted, obtains the hemoglobin concentration of whole blood sample.
Plasma lipid component is than operational part 50, its hemoglobin concentration based on the first sample, default plasma lipid into
Divide rate constant bSlurryAnd haemocyte liquid component rate constant bBorn of the same parents, determine plasma lipid component ratio b1.Specifically, blood plasma liquid
Body component ratio b1=(bSlurry+ V1×bBorn of the same parents)/(1+ V1), wherein bSlurryFor plasma lipid component ratio constant, bBorn of the same parentsFor haemocyte liquid
Component ratio constant, V1For the broken haemocyte/blood plasma ratio determined according to the hemoglobin concentration of the first sample.It can preset,
Such as haemocyte liquid component rate constant bBorn of the same parentsFor 65%, the plasma lipid component ratio constant bSlurryFor 90%.Wherein, according to
The hemoglobin concentration of sample determine haemocyte/blood plasma than method can use the prior art as in 201110166156.3
Method determines.Since the first sample is handled by haemolysis, its obtained haemocyte/blood plasma is than to be broken in blood sample
Haemocyte/blood plasma ratio.
Haemocyte/blood plasma is than calculating part 60, and based on the hemoglobin concentration of the first sample, the second sample is blood red after haemolysis
Protein concentration, calculates haemocyte/blood plasma in blood sample and compares Vb.Specifically, haemocyte/blood plasma compares V in blood sampleb=V2-
V1, wherein V2For the haemocyte/blood plasma ratio determined according to the whole blood sample after the second sample haemolysis, V1For according to the first sample
The broken haemocyte that hemoglobin concentration determines/blood plasma ratio.
Whole blood liquid component is than operational part 70, and blood is thin in the blood sample calculated based on haemocyte/blood plasma than calculating part 60
Born of the same parents/blood plasma compares Vb, determine the liquid component ratio b2 of the whole blood of blood sample.Specifically, the liquid of the whole blood of blood sample into
Divide ratio b2=a1×bSlurry+ a2×bBorn of the same parents；Wherein a2For haemocyte/whole blood ratio of whole blood sample after the second sample haemolysis, a2=Vb/
(Vb+ 1), a1For blood plasma/whole blood ratio of whole blood sample after the second sample haemolysis, a1=1-a2。
Plasma glucose calculating part 80, the liquid component ratio based on the whole blood liquid component whole blood more definite than operational part 70
The plasma lipid component ratio b1 and the second of the detection of glucose detection portion 30 that b2, plasma lipid component are determined than operational part 50
The concentration of glucose ρ 1 of whole blood sample after sample haemolysis, determines concentration of glucose in blood plasma.Specifically, glucose is dense in blood plasma
Spend 1 × b1/b2 of ρ=ρ.
As seen through the above description of the embodiments, those skilled in the art can be understood that the present invention can
Realized by the mode of software plus required general hardware platform.Based on such understanding, technical scheme essence
On the part that contributes in other words to the prior art can be embodied in the form of software product, the computer software product
It can be stored in storage medium, such as ROM/RAM, magnetic disc, CD, including some instructions are with so that a computer is set
Standby (can be personal computer, server, either network equipment etc.) performs certain of each embodiment of the present invention or embodiment
Method described in a little parts.
All references mentioned in the present invention all incorporated by reference in this application, are individually recited just as each document
As reference.In addition, it should also be understood that, after the above disclosure of the present invention has been read, protection scope of the present invention is not
Above-described embodiment is limited only to, those skilled in the art can make various modifications or changes to the present invention, is not departing from the present invention
Under the premise of principle, these equivalent forms also fall within the scope of the appended claims of the present application.
Claims (7)
1. a kind of blood sample analysis tests system, including：Haemolysis processing unit, for carrying out haemolysis to receiving sample；Glucose
Test section, the concentration of glucose of sample is received for detecting；Hemoglobin test section, the hemoglobin of sample is received for detecting
Concentration；Haemocyte/blood plasma is than calculating part, for calculating haemocyte in blood sample/blood plasma ratio；Whole blood liquid component compares computing
Portion, the liquid component ratio of the whole blood for calculating blood sample；Plasma glucose calculating part, it is used to calculate plasma glucose
Concentration；It is characterized in that：Sample division is further included, plasma lipid component is than operational part and control unit；The sample division
The blood sample of input test system is divided into the first sample and the second sample by portion；Control unit controls the hemoglobin inspection
Survey portion determines the hemoglobin concentration of first sample；The plasma lipid component is than operational part based on first sample
Hemoglobin concentration, determines plasma lipid component ratio；The control unit control second sample by haemolysis processing unit into
After the processing of row haemolysis, the grape of the second sample after the glucose detection portion and hemoglobin test section detection haemolysis is controlled
Sugared concentration and hemoglobin concentration；For the haemocyte/blood plasma than calculating part, the hemoglobin based on first sample is dense
Spend, the hemoglobin concentration of the second sample after haemolysis, calculates haemocyte/blood plasma ratio in blood sample；The whole blood liquid component
Than operational part, haemocyte/blood plasma ratio, determines blood sample in the blood sample calculated based on haemocyte/blood plasma than calculating part
The liquid component ratio of whole blood；Plasma glucose calculating part, the liquid based on whole blood liquid component than whole blood that operational part determines
The plasma lipid component ratio and the haemolysis of glucose detection portion detection that component ratio, plasma lipid component are determined than operational part
The concentration of glucose of the second sample afterwards, determines concentration of glucose in blood plasma.
2. blood sample analysis according to claim 1 tests system, it is characterised in that：The haemocyte/blood plasma is than meter
Calculation portion, based on the hemoglobin concentration of first sample, the hemoglobin concentration of the second sample after haemolysis, calculates blood sample
Middle haemocyte/blood plasma compares Vb=V2- V1, wherein V2It is thin for the blood that is determined according to the hemoglobin concentration of the second sample after haemolysis
Born of the same parents/blood plasma ratio, V1For the broken haemocyte/blood plasma ratio determined according to the hemoglobin concentration of the first sample.
3. the blood sample analysis test system according to claim 1-2, it is characterised in that：The whole blood liquid component
Following formula, which is based on, than operational part calculates whole blood liquid component ratio b2=a1×bSlurry+ a2×bBorn of the same parents；Wherein a2For the second sample after haemolysis
Haemocyte/whole blood ratio, a2=Vb/(Vb+ 1), a1For blood plasma/whole blood ratio of the second sample after haemolysis, a1=1-a2。
4. blood sample analysis according to claim 3 tests system, it is characterised in that：The plasma glucose calculating part
Concentration of glucose 1 × b1/b2 of ρ=ρ in blood plasma are calculated based on following formula, wherein ρ 1 is the after the haemolysis of glucose detection portion detection
The concentration of glucose of two samples.
5. the blood sample analysis test system according to claim 3-4, it is characterised in that：The hemoglobin detection
Portion measures the hemoglobin concentration for receiving sample based on absorption photometry.
6. blood sample analysis according to claim 5 tests system, it is characterised in that：The glucose detection portion is based on
Enzyme Electrode measurement receives the concentration of glucose of sample.
7. blood sample analysis according to claim 6 tests system, it is characterised in that：The glucose detection portion is based on
Enzymic colorimetric determines to receive the concentration of glucose of sample.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711356235.4A CN107941722B (en) | 2017-12-16 | 2017-12-16 | Blood sample analysis and test system |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711356235.4A CN107941722B (en) | 2017-12-16 | 2017-12-16 | Blood sample analysis and test system |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN107941722A true CN107941722A (en) | 2018-04-20 |
| CN107941722B CN107941722B (en) | 2021-01-15 |
Family
ID=61943621
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201711356235.4A Active CN107941722B (en) | 2017-12-16 | 2017-12-16 | Blood sample analysis and test system |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107941722B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108606926A (en) * | 2018-05-02 | 2018-10-02 | 李振 | A kind of medical use liquid storage shatter-resistant vial |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1522369A (en) * | 2002-03-29 | 2004-08-18 | ���µ�����ҵ��ʽ���� | Blood processing method, blood processing device, method of measuring hemoglobins and device for measuring hemoglobins |
| CN102313815A (en) * | 2010-06-23 | 2012-01-11 | 爱科来株式会社 | The plasma glucose assay method |
-
2017
- 2017-12-16 CN CN201711356235.4A patent/CN107941722B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1522369A (en) * | 2002-03-29 | 2004-08-18 | ���µ�����ҵ��ʽ���� | Blood processing method, blood processing device, method of measuring hemoglobins and device for measuring hemoglobins |
| CN102313815A (en) * | 2010-06-23 | 2012-01-11 | 爱科来株式会社 | The plasma glucose assay method |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108606926A (en) * | 2018-05-02 | 2018-10-02 | 李振 | A kind of medical use liquid storage shatter-resistant vial |
Also Published As
| Publication number | Publication date |
|---|---|
| CN107941722B (en) | 2021-01-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Kulkarni et al. | Analysis of blood glucose measurements using capillary and arterial blood samples in intensive care patients | |
| Berkow | Factors affecting hemoglobin measurement | |
| Beardsall | Measurement of glucose levels in the newborn | |
| Verwaerde et al. | The accuracy of the i-STAT portable analyser for measuring blood gases and pH in whole-blood samples from dogs | |
| US20220412883A1 (en) | Method and Apparatus for Non-Invasively Measuring Blood Circulatory Hemoglobin | |
| Burritt | Current analytical approaches to measuring blood analytes | |
| Chen et al. | Analytical evaluation of the epoc® point-of-care blood analysis system in cardiopulmonary bypass patients | |
| Shearer et al. | Comparison of glucose point-of-care values with laboratory values in critically ill patients | |
| Janssen et al. | Importance of the pre-analytical phase in blood glucose analysis | |
| Wahl | How accurately do we measure blood glucose levels in intensive care unit (ICU) patients? | |
| Ng et al. | Accuracy and reliability of the i-STAT point-of-care device for the determination of haemoglobin concentration before and after major blood loss | |
| CN107941722A (en) | Blood sample analysis tests system | |
| Lalande et al. | Determination of blood volume by pulse CO-oximetry | |
| CN108169155A (en) | A kind of blood sample analysis tests system | |
| CN108107195B (en) | Blood sample analysis test method | |
| Breenfeldt Andersen et al. | A semi-automated device rapidly determine circulating blood volume in healthy males and carbon monoxide uptake kinetics of arterial and venous blood | |
| Trulock III | Arterial blood gases | |
| US7291502B2 (en) | Method for performing a non-invasive blood gas test | |
| Yamauchi et al. | Circulating blood volume measurements correlate poorly with pulmonary artery catheter measurements. | |
| Schreur et al. | Use of the CDI blood parameter monitoring system 500 for continuous blood gas measurement during extracorporeal membrane oxygenation simulation | |
| Kellum | Making strong ion difference the" Euro" for bedside acid-base analysis | |
| Khine et al. | Correlation between self-monitored mean blood glucose and average plasma glucose estimated from glycated haemoglobin in patients attending the diabetes clinic at Dr George Mukhari Academic Hospital, Pretoria, South Africa | |
| US20240016421A1 (en) | Remote blood volume monitor | |
| Ganter et al. | Accuracy and performance of a modified continuous intravascular blood gas monitoring device during thoracoscopic surgery | |
| Khositseth et al. | Accuracy of bedside glucometry in critically ill children with peripheral hypoperfusion |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| TA01 | Transfer of patent application right | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20201229 Address after: No.550014, gaoguhai National Science and Technology Development Zone, Guiyang City, Guizhou Province Applicant after: GUIZHOU KINGMED DIAGNOSTICS INSPECTION CENTER Co.,Ltd. Address before: 350000 29 new power road, Gulou District, Fuzhou, Fujian Applicant before: Huang Youfeng |
|
| GR01 | Patent grant | ||
| GR01 | Patent grant |